Collaborative Management of Women with Bipolar Disorder During Pregnancy and Postpartum: Pharmacologic Considerations

Journal of Midwifery and Women's Health

Volumn 52, Issue 1, 2007, Pages 3-13

  Ward, Sheila ^a   Wisner, Katherine L ^a  

^a NONE

Author keywords

antimanic drugs; antipsychotics; bipolar disorder; contraception; depression; lactation; lithium; mood stabilizers; postpartum; pregnancy

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; CONTRACEPTIVE AGENT; FOLIC ACID; HALOPERIDOL; LAMOTRIGINE; LEVONORGESTREL; LITHIUM; MEDROXYPROGESTERONE ACETATE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PERPHENAZINE; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; QUETIAPINE; RISPERIDONE; TIAGABINE; TOPIRAMATE; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VALPROIC ACID DERIVATIVE; VITAMIN K GROUP; ZIPRASIDONE;

ARTICLE; BIPOLAR DISORDER; CHRONIC DISEASE; COMBINATION CHEMOTHERAPY; DATA COLLECTION METHOD; DEPRESSION; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTONIA; EBSTEIN ANOMALY; EXTRAPYRAMIDAL SYMPTOM; FAMILY LIFE; FIRST TRIMESTER PREGNANCY; HIGH RISK BEHAVIOR; HIGH RISK PATIENT; HUMAN; INTERPERSONAL COMMUNICATION; INVOLUNTARY MOVEMENT; LACTATION; MANIA; MIXED MANIA AND DEPRESSION; MONOTHERAPY; MUSCLE CONTRACTION; MUSCLE HYPERTONIA; NEURAL TUBE DEFECT; OBSTETRICS; PARKINSONISM; PATIENT EDUCATION; PREGNANCY DIABETES MELLITUS; PREGNANCY DISORDER; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; PUERPERIUM; RECOMMENDED DRUG DOSE; REGISTER; RELAPSE; REPRODUCTIVE TOXICITY; RESTLESSNESS; RIGIDITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCREENING TEST; SIDE EFFECT; SODIUM INTAKE; SODIUM RESTRICTION; STEVENS JOHNSON SYNDROME; SUICIDE; TEAMWORK; TERATOGENICITY; TREMOR; VITAMIN K DEFICIENCY; WEIGHT GAIN;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MATERNAL HEALTH SERVICES; MIDWIFERY; NURSE'S ROLE; PATIENT EDUCATION; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENCE;

EID: 33845864442     PISSN: 15269523     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmwh.2006.09.002     Document Type: Article

References (50)

1. Hirschfeld R.M., Calabrese J.R., Weissman M.M., Reed M., Davies M.A., Frye M.A., et al. Screening for bipolar disorder in the community. J Clin Psychiatry 64 (2003) 53-59
2. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159 Suppl 4 (2002) 1-50
3. American Psychiatric Association. American Psychiatric Association Task Force on Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR (2000), American Psychiatric Association, Washington, DC
4. Suppes T., and Keck P. Bipolar disorder treatment & management (2005), Compact Clinicals, Kansas City, MO
5. Swann A.C., Dougherty D.M., Pazzaglia P.J., Pham M., Steinberg J.L., and Moeller F.G. Increased impulsivity associated with severity of suicide attempt history in patients with bipolar disorder. Am J Psychiatry 162 (2005) 1680-1687
6. Baldessarini R.J., Tondo L., and Hennen J. Treatment delays in bipolar disorders. Am J Psychiatry 156 (1999) 811-812
7. Gijsman H.J., Geddes J.R., Rendell J.M., Nolen W.A., and Goodwin G.M. Antidepressants for bipolar depression: A systematic review of randomized, controlled trials. Am J Psychiatry 61 (2004) 1537-1547
8. Swann A.C., Geller B., Post R.M., Altshuler L., Chang K.D., Delbello M.P., et al. Prim Care Companion. J Clin Psychiatry 7 (2005) 15-21
9. Wisner K.L., Zarin D.A., Holmboe E.S., Appelbaum P.S., Gelenburg A.J., Leonard H.L., et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 157 (2000) 1933-1940
10. Yonkers K.A., Wisner K.L., Stowe Z., Leibenluft E., Cohen L., Miller L., et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 161 (2004) 608-620
11. Viguera A.C., Nonacs R., Cohen L.S., Tondo L., Murray A., and Baldessarini R.J. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 157 (2000) 179-184
12. Nonacs R., and Cohen L.S. Assessment and treatment of depression during pregnancy: An update. Psychiatr Clin North Am 26 (2003) 547-562
13. Curtis V. Women are not the same as men: Specific clinical issues for female patients with bipolar disorder. Bipolar Disord 7 Suppl 1 (2005) 16-24
14. Jacobson S.J., Jones K., Johnson K., Ceolin L., Kauer P., Sahn K., et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 339 (1992) 530-533
15. Schou M., Goldfield M.D., Weinstein M.R., and Vileneuve A. Lithium and pregnancy, I: Report from the register of lithium babies. BMJ 2; (1973) 135-136
16. Cohen L.S., Friedman J.M., Jefferson J.W., Johnson E.M., and Weiner M.L. A reevaluation of risk of in utero exposure to lithium. JAMA 271 (1994) 146-150
17. Schou M. What happened later to the lithium babies?. A follow-up study of children born without malformations. Acta Psychiatr Scand 54 (1976) 193-197
18. Briggs G.G. In: Briggs G.G., Freeman R.K., and Yaffe S.J. (Eds). Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. sixth edition (2005), Lippincott Williams & Wilkins, Philadelphia
19. Pinelli J., Symington A., Cunningham K., and Bosco A. Case report and review of the perinatal implications of maternal lithium use. Am J Obstet Gynecol 186 (2002) 245-249
20. Newport D., Viguera A., Beach B., Ritchie J., Cohen L., and Stowe Z. Lithium placental passage and obstetrical outcome: Implications for clinical management during late pregnancy. Am J Psychiatry 162 (2005) 2162-2170
21. El-Mallakh R.S. Lithium actions and mechanisms (1996), American Psychiatric Press Inc, Washington, DC
22. Cipriani A., Pretty H., Hawton K., and Geddes J.R. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 162 (2005) 1805-1819
23. Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 4 (2005) 781-786
24. Wyszynski D.F., Nambisan M., Surve T., Alsdorf R.M., Smith C.R., Holmes L.B., and Antiepileptic Drug Pregnancy Registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64 (2005) 961-965
25. Jager-Roman E. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 108 (1986) 997-1004
26. Diav-Citrin O., Shechtman S., Arnon J., and Ornoy A. Is carbamazepine teratogenic?. A prospective controlled study of 210 pregnancies. Neurology 57 (2001) 321-324
27. Dominguez Salgado M., Morales A., Santiago Gomez R., Diaz-Obregon M., and Arraball M. Gestational lamotrigine monotherapy: Congenital malformations on psychomotor development. [abstract]. Epilepsia 45 Suppl 7 (2004) 229-230
28. Adab N., Jacoby A., Smith D., and Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 70 (2001) 15-21
29. Gaily E., Kantola-Sorsa E., Hiilesmaa V., Isoaho M., Matila R., Kotila M., et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 62 (2004) 28-32
30. Mackay F., O'Brien T., and Hitchcock A. Safety of long-term lamotrigine in epilepsy. Epilepsia 38 (1997) 881-886
31. Thisted E., and Ebbesen R. Malformations, withdrawal manifestations, and hypoglycemia after exposure to valproate in utero. Arch Dis Child 69 (1993) 288-291
32. Yerby M.S. Special considerations for women with epilepsy. Pharmacotherapy 20 (2000) 159S-170S
33. Pennell P.B., Newport D.J., Stowe Z.N., Helmers S.L., Montgomery J.Q., and Henry T.R. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 62 (2004) 292-295
34. Sullivan J.R., and Shear N.H. The drug hypersensitivity syndrome: What is the pathogenesis?. Arch Dermatol 137 (2001) 357-364
35. Dean J.C.S., Hailey H., Moore S.J., Lloyd D.J., Turnpenny P.D., and Little J. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 39 (2002) 251-259
36. Meador K., Baker G.A., Clayton Smith J., Pennell P., Liporace J., Kalavjian L., et al. Differential effects of antiepileptic drugs on serious adverse outcomes in children exposed in utero. Epilepsia 45 (2004) 48
37. Meischenguiser R., D'Giano C., and Ferro S. Major malformations in offspring of women with epilepsy. Neurology 61 (2003) 1631
38. Slone D., Siskind V., Heinonen O.P., Monson R.R., Kaufman D.W., and Shapiro S. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 128 (1977) 486-488
39. Auerbach J.G., Hans S.L., Marcus J., and Maeir S. Maternal psychotropic medication and neonatal behavior. Neurotoxicol Teratol 14 (1992) 399-406
40. Desmond M.M., Rudolph A.H., and Hill R.M. Behavioral alterations in infants born to mothers on psychoactive medications during pregnancy. In: Farrell G. (Ed). Congenital mental retardation (1967), University of Texas, Austin, TX
41. McKenna K., Koren G., Tetelbaum M., Wilton L., Shakir S., Diav-Citrin O., et al. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. J Clin Psychiatry 66 (2005) 444-449
42. Viguera A.C., Cohen L.S., Baldessarini R.J., and Nonacs R. Managing bipolar disorder during pregnancy: Weighing the risks and benefits. Can J Psychiatry 47 (2002) 426-436
43. Altshuler L., Richards M., and Yonkers K. Treating bipolar disorder during pregnancy. Curr Psychiatry 2 (2003) 14-26
44. Kendell R.E., Chalmers J.C., and Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry 150 (1987) 662-673
45. Mattson R.H., Cramer J.A., Darney P.D., and Naftolin F. The use of oral contraceptives by women with epilepsy. JAMA 256 (1986) 238-240
46. Haukkamaa M. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception 33 (1986) 559-565
47. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 16 (2002) 263-272
48. Sabers A., Ohman I., Christensen J., and Tomson T. Oral contraceptives reduce lamotrigine plasma levels reduced by oral contraceptives. Neurology 61 (2003) 570-571
49. Frank E., Swartz H., and Kupfer D. Interpersonal and social rhythm therapy: Managing the chaos of bipolar disorder. Biol Psychiatry 48 (2000) 593-604
50. Reimann D., Voderholzer U., and Berger M. Sleep and sleep-wake manipulations in bipolar depression. Neuropsychobiology 45 Suppl 1 (2002) 7-12